Hypertension (high blood pressure) affects between 30-40 percent of adults throughout the world. While many adults can regulate their high blood pressure with medication and lifestyle changes, for some these options simply are not enough due to the cost or side effects of the necessary medications.
For those patients, a different approach to combat high blood pressure is necessary.
The CAMC Clinical Trials Center, through its innovative medical research, recently offered an advanced treatment option called Spyral HTN for individuals dealing with chronic high blood pressure. CAMC is the first site in West Virginia participating in this trial and enrolled its first patient in November.
High blood pressure occurs when the renal nerves that control the kidneys become overactive, thereby causing the blood pressure to rise. The Spyral HTN clinical trial program focuses on reducing blood pressure and ultimately limiting damage to the patient’s heart, kidney and blood vessels through an investigational procedure known as renal denervation.
“The Spyral HTN medical study for hypertension is a unique study to evaluate the role of renal denervation in patients with mild to moderate hypertension,” said Aravinda Nanjundappa, MD, interventional cardiologist. “The results of the study will be pivotal in paving the path for treatment of hypertension with denervation.”
This procedure uses the Symplicity Spyral™ catheter, which is inserted in the groin area through a small tube. Imaging is then used to advance the catheter through the tube. The catheter stops at multiple locations in the artery to adjust the renal nerves with heat by radio frequency in order to help disrupt and balance the overactive signaling that is being sent to and from the kidneys.
This innovative therapy is a minimally-invasive procedure that can be performed in a single session.
Patients who are eligible for this trial undergo multiple screening tests and follow-up appointments with the study doctor to ensure a safe and effective experience.
“We in WV have a high rate of hypertension and cardiovascular disease burden compared to the rest of the United States,” Nanjundappa said. “An innovative treatment option such as renal denervation can be a game changer in patient care.”
The CAMC Clinical Trials Center is currently recruiting for the Spyral HTN clinical trial program. Call (304) 388-9944 for more information.